The user started with Finasteride at 19, added Dutasteride and Minoxidil at 26, but continues to experience hair loss. Suggestions include checking health markers, considering genetics, and possibly increasing Minoxidil dosage.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
Dutasteride may not be effective for everyone due to underlying issues, suggesting scalp biopsies for further diagnosis. Users discuss using higher doses of dutasteride, topical treatments, minoxidil, and pyrilutamide for hair loss management.